Case series reveals serum biomarker changes during treatment in bullous pemphigoid, indicating possible monitoring utility.
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Table S1: Serial changes in BPDAI, anti-BP180NC16A antibody titers, and serum SCCA2 levels during the treatment course. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Kitayama et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: